MX2015007853A - Diazol amidas. - Google Patents
Diazol amidas.Info
- Publication number
- MX2015007853A MX2015007853A MX2015007853A MX2015007853A MX2015007853A MX 2015007853 A MX2015007853 A MX 2015007853A MX 2015007853 A MX2015007853 A MX 2015007853A MX 2015007853 A MX2015007853 A MX 2015007853A MX 2015007853 A MX2015007853 A MX 2015007853A
- Authority
- MX
- Mexico
- Prior art keywords
- diazole
- ccr1
- amides
- compounds
- antagonists
- Prior art date
Links
- -1 Diazole amides Chemical class 0.000 title abstract 2
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 abstract 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000004500 CCR1 Receptors Human genes 0.000 abstract 1
- 108010017319 CCR1 Receptors Proteins 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000002860 competitive effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745444P | 2012-12-21 | 2012-12-21 | |
| PCT/US2013/077257 WO2014100735A2 (en) | 2012-12-21 | 2013-12-20 | Diazole amides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015007853A true MX2015007853A (es) | 2015-09-29 |
Family
ID=50975330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015007853A MX2015007853A (es) | 2012-12-21 | 2013-12-20 | Diazol amidas. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9169248B2 (enExample) |
| EP (1) | EP2935227B1 (enExample) |
| JP (1) | JP6306607B2 (enExample) |
| CN (1) | CN104918921B (enExample) |
| AU (1) | AU2013364038B2 (enExample) |
| CA (1) | CA2894715C (enExample) |
| DK (1) | DK2935227T3 (enExample) |
| ES (1) | ES2648994T3 (enExample) |
| MX (1) | MX2015007853A (enExample) |
| PT (1) | PT2935227T (enExample) |
| WO (1) | WO2014100735A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2666730C2 (ru) | 2012-12-07 | 2018-09-12 | Кемосентрикс, Инк. | Диазольные лактамы |
| CN104918921B (zh) | 2012-12-21 | 2017-09-22 | 凯莫森特里克斯股份有限公司 | 二唑酰胺 |
| WO2016202759A1 (en) * | 2015-06-18 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Cytotoxic substituted 2-(1 h-pyrazol-1 -yl)-1,3-benzothiazole compounds for the treatment of cancer |
| WO2016202758A1 (en) * | 2015-06-18 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds |
| BR112018070361A2 (pt) | 2016-04-07 | 2019-01-29 | Chemocentryx Inc | redução da carga tumoral através da administração de antagonistas do ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1 |
| MA53096A (fr) * | 2018-07-03 | 2021-05-12 | Ifm Due Inc | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting |
| CN114206338B (zh) | 2019-07-10 | 2025-12-12 | 凯莫森特里克斯股份有限公司 | 作为pd-l1抑制剂的二氢化茚类 |
| PE20221445A1 (es) | 2019-10-16 | 2022-09-21 | Chemocentryx Inc | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 |
| CR20220216A (es) | 2019-10-16 | 2023-01-09 | Chemocentryx Inc | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2012100A (en) * | 1931-12-17 | 1935-08-20 | Edwin Pierce Weber | Liquid fuel burner |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
| US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
| US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
| US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
| WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
| EP0470246B1 (en) | 1990-02-28 | 1995-06-28 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
| US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
| US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
| US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
| DE19539091A1 (de) * | 1995-10-20 | 1997-04-24 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung |
| CA2229617A1 (en) * | 1995-10-20 | 1997-05-01 | Dr. Karl Thomae Gmbh | 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| US5833651A (en) | 1996-11-08 | 1998-11-10 | Medtronic, Inc. | Therapeutic intraluminal stents |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| GT200100147A (es) * | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
| US6756385B2 (en) * | 2000-07-31 | 2004-06-29 | Pfizer Inc. | Imidazole derivatives |
| WO2002024656A1 (en) * | 2000-09-22 | 2002-03-28 | Nihon Nohyaku Co., Ltd. | N-(4-pyrazolyl)amide derivatives, chemicals for agricultural and horticultural use, and usage of the same |
| US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
| WO2004099156A1 (en) | 2003-05-01 | 2004-11-18 | Bristol-Myers Squibb Company | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors |
| US7381714B2 (en) | 2005-05-19 | 2008-06-03 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| ES2430821T3 (es) * | 2006-10-10 | 2013-11-21 | Amgen Inc. | Compuestos de N-arilpirazol para usar contra la diabetes |
| EP3663295A1 (en) * | 2007-06-22 | 2020-06-10 | Eli Lilly And Co. | 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel |
| WO2009137338A1 (en) * | 2008-05-06 | 2009-11-12 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
| US20120108614A1 (en) * | 2008-05-14 | 2012-05-03 | Chong Jayhong A | Compounds and compositions for treating chemical warfare agent-induced injuries |
| EP2352730A4 (en) * | 2008-11-07 | 2012-04-25 | Lundbeck & Co As H | BIOLOGICAL ACTIVE AMIDE |
| GB0915892D0 (en) * | 2009-09-10 | 2009-10-14 | Smithkline Beecham Corp | Compounds |
| RU2666730C2 (ru) * | 2012-12-07 | 2018-09-12 | Кемосентрикс, Инк. | Диазольные лактамы |
| CN104918921B (zh) | 2012-12-21 | 2017-09-22 | 凯莫森特里克斯股份有限公司 | 二唑酰胺 |
-
2013
- 2013-12-20 CN CN201380067710.XA patent/CN104918921B/zh active Active
- 2013-12-20 WO PCT/US2013/077257 patent/WO2014100735A2/en not_active Ceased
- 2013-12-20 EP EP13866291.1A patent/EP2935227B1/en active Active
- 2013-12-20 DK DK13866291.1T patent/DK2935227T3/en active
- 2013-12-20 JP JP2015549830A patent/JP6306607B2/ja active Active
- 2013-12-20 MX MX2015007853A patent/MX2015007853A/es active IP Right Grant
- 2013-12-20 AU AU2013364038A patent/AU2013364038B2/en active Active
- 2013-12-20 CA CA2894715A patent/CA2894715C/en active Active
- 2013-12-20 ES ES13866291.1T patent/ES2648994T3/es active Active
- 2013-12-20 US US14/137,479 patent/US9169248B2/en active Active
- 2013-12-20 PT PT138662911T patent/PT2935227T/pt unknown
-
2015
- 2015-10-08 US US14/878,784 patent/US9750722B2/en active Active
-
2017
- 2017-07-25 US US15/659,488 patent/US10342781B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013364038B2 (en) | 2018-04-05 |
| EP2935227A2 (en) | 2015-10-28 |
| CN104918921A (zh) | 2015-09-16 |
| US9750722B2 (en) | 2017-09-05 |
| US20140179733A1 (en) | 2014-06-26 |
| WO2014100735A2 (en) | 2014-06-26 |
| CN104918921B (zh) | 2017-09-22 |
| US20180071257A1 (en) | 2018-03-15 |
| WO2014100735A3 (en) | 2014-08-14 |
| US10342781B2 (en) | 2019-07-09 |
| CA2894715C (en) | 2021-06-15 |
| DK2935227T3 (en) | 2017-12-04 |
| ES2648994T3 (es) | 2018-01-09 |
| US20160193185A1 (en) | 2016-07-07 |
| JP2016507504A (ja) | 2016-03-10 |
| EP2935227B1 (en) | 2017-09-13 |
| CA2894715A1 (en) | 2014-06-26 |
| EP2935227A4 (en) | 2016-05-18 |
| US9169248B2 (en) | 2015-10-27 |
| JP6306607B2 (ja) | 2018-04-04 |
| PT2935227T (pt) | 2017-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015007051A (es) | Diazol lactamas. | |
| MX2015007853A (es) | Diazol amidas. | |
| PH12013501136A1 (en) | Lysophosphatidic acid receptor antagonists and uses thereof | |
| MX379110B (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| TN2012000126A1 (en) | Polycyclic compounds as lysophosphatidic acid receptor antagonists | |
| MY193728A (en) | Muscarinic receptor agonists | |
| MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
| IN2012DN02735A (enExample) | ||
| IN2012DN00754A (enExample) | ||
| TN2015000250A1 (en) | Novel benzimidazole derivatives as ep4 antagonists | |
| EP2155203A4 (en) | Azaindazole compounds and methods of use | |
| CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
| PH12014500355A1 (en) | Lysophosphatidic acid receptor antagonists | |
| PH12015501339A1 (en) | Indole carboxamide derivatives as p2x7 receptor antagonists | |
| PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
| EA201500112A1 (ru) | 3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств | |
| HK1218543A1 (zh) | 新型磺酰胺trpa1受体拮抗剂 | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| IL217759A (en) | Pyrolidine derivatives as 3nk receptor antagonists, pharmaceuticals containing them, process for preparation, and use thereof for drug preparation | |
| MX2015002514A (es) | Antagonistas de los receptores de quimiocina. | |
| MX2015005312A (es) | Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12. | |
| PL402030A1 (pl) | Nowe pochodne tiosemikarbazonów, ich kompozycje farmaceutyczne oraz ich zastosowanie | |
| CY1115482T1 (el) | Πολυκυκλικοι ανταγωνιστες υποδοχεων λυσοφωσφατιδικου οξεος | |
| UA105703C2 (uk) | 7-бром-5-феніл-3-ариламіно-1,2-дигідро-3н-1,4-бенздіазепін-2-они як анальгетичні агенти |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |